KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Goodwill (2016 - 2026)

Pacira BioSciences has reported Goodwill over the past 15 years, most recently at $19.8 million for Q1 2026.

  • For Q1 2026, Goodwill fell 7.99% year-over-year to $19.8 million; the TTM value through Mar 2026 reached $19.8 million, down 7.99%, while the annual FY2025 figure was $20.2 million, N/A changed from the prior year.
  • Goodwill for Q1 2026 was $19.8 million at Pacira BioSciences, down from $20.2 million in the prior quarter.
  • Over five years, Goodwill peaked at $163.2 million in Q4 2022 and troughed at $19.8 million in Q1 2026.
  • A 5-year average of $112.9 million and a median of $157.4 million in 2022 define the central range for Goodwill.
  • Biggest five-year swings in Goodwill: skyrocketed 58.12% in 2022 and later tumbled 87.56% in 2025.
  • Year by year, Goodwill stood at $163.2 million in 2022, then changed by 0.0% to $163.2 million in 2023, then dropped by 0.03% to $163.2 million in 2024, then crashed by 87.62% to $20.2 million in 2025, then fell by 1.98% to $19.8 million in 2026.
  • Business Quant data shows Goodwill for PCRX at $19.8 million in Q1 2026, $20.2 million in Q4 2025, and $20.3 million in Q3 2025.